Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported FCF Margin of 943.28% for Q1 2026, down 82322.0% on a YoY basis from N/an in Q1 2025, and down 314.65% quarter-over-quarter from 227.49% in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported FCF Margin for 9 years, with the latest figure at 943.28% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 82322.0% year-over-year to 943.28%; the trailing twelve-month figure through Mar 2026 stood at 107.23% (down 4468.0% YoY), and the FY2025 full-year result was 90.82%, down 5117.0% from the prior year.
- FCF Margin for Q1 2026 stood at 943.28%, down from 227.49% in the prior quarter.
- The five-year high for FCF Margin was 478.53% in Q2 2023, with the low at 975.4% in Q1 2022.
- Historically, FCF Margin has averaged 149.28% across 5 years, with a median of 61.11% in 2024.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 152601 bps — and 2026, when it plunged 82322 bps.
- Arcturus Therapeutics Holdings' FCF Margin stood at 97.6% in 2022, then tumbled by 105 bps to 4.87% in 2023, then surged by 74 bps to 1.25% in 2024, then plunged by 18136 bps to 227.49% in 2025, then sank by 315 bps to 943.28% in 2026.
- The last three FCF Margin figures came in at 943.28% (Q1 2026), 227.49% (Q4 2025), and 99.71% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -943.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -943.28% |
| Dec 31, 2025 | -227.49% |
| Sep 30, 2025 | -99.71% |
| Jun 30, 2025 | -20.33% |
| Mar 31, 2025 | -120.06% |
| Dec 31, 2024 | -1.25% |
| Sep 30, 2024 | -57.22% |
| Jun 30, 2024 | -61.11% |
| Mar 31, 2024 | -15.25% |
| Dec 31, 2023 | -4.87% |
| Sep 30, 2023 | -75.00% |
| Jun 30, 2023 | 478.53% |
| Mar 31, 2023 | -44.81% |
| Dec 31, 2022 | 97.60% |
| Sep 30, 2022 | -333.55% |
| Jun 30, 2022 | -134.51% |
| Mar 31, 2022 | -975.40% |
| Dec 31, 2021 | -694.89% |
| Sep 30, 2021 | -755.81% |
| Jun 30, 2021 | -1,660.52% |